Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance
Asparaginase is one of the most important chemotherapeutic agents against pediatric acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. The therapeutic efficacy (e.g., chemoresistance) and adverse effects of asparaginase (e.g., hypersensivity and pancreatitis) have been inv...
Saved in:
Main Author: | Shih-Hsiang Chen (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2015-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
by: Luke Maese, et al.
Published: (2022) -
Coagulation abnormality as a complication of L-asparaginase therapy in childhood lymphoblastic leukemia
by: Djajadiman Gatot, et al.
Published: (2016) -
A study of the adverse drug reactions of L-asparaginase in newly diagnosed children with acute lymphoblastic leukemia
by: Harshada Uchil, et al.
Published: (2017) -
L-asparaginase induced acute pancreatitis in children with acute lymphoblastic leukemia and its impact on outcome
by: Siddhartha Reddy Dodda, et al.
Published: (2024) -
Concurrent diabetic ketoacidosis and pancreatitis in Paediatric acute lymphoblastic leukemia receiving L-asparaginase
by: Patel Zeeshan Jameel, et al.
Published: (2020)